Tikcro Technologies Ltd., powered by a novel 3D antigen design technology, generates new ‎antibodies that block receptor/ligand surface domains of immune modulators and re-‎activate the body’s immune system to fight cancer. Our antibodies are in various pre-‎clinical stages.

Following extensive collaborative research with the Weizmann Institute of Science in ‎Israel, we are developing drug-candidates by leveraging a unique antigen design ‎technology for the generation of new functional blocking antibodies. This approach has ‎shown early success with pipeline below. Going forward, in 2017-2018 we plan to advance ‎with early-stage candidates to rigorous pre-clinical trials and aim to build sufficient data for ‎further progress and clinical trials.‎

Early stage pipeline

Immune Oncology

Clinical Indications:
Metastatic melanoma

Immune Oncology

Key Advantages

  • Higher certainty and fast antibody generation of targeted-specific antibodies
  • Selective blocking of a single target among a closely related group of targets, which allows:
    • Specific and exclusive blocking of the ligand/receptor binding domain, aiming to increase patient response rate
    • Eliminating binding of conflicting ligands/receptors such as inhibitory versus activatory modulators typical to immune checkpoint functions
© Copyright 2015, Tikcro Ltd. | Legal - Terms of use | All rights reserved | Site by Imaginet